
|Videos|October 12, 2017
Fosfomycin: A Novel Epoxide Antimicrobial
Author(s)Contagion® Editorial Staff
Evelyn J. Ellis-Grosse, PhD, chief scientific officer of Zavante Therapeutics, explains why Zavante Therapeutic’s fosfomycin is a unique, novel antimicrobial.
Advertisement
Evelyn J. Ellis-Grosse, PhD, chief scientific officer of Zavante Therapeutics, explains why Zavante Therapeutic’s fosfomycin is a novel antimicrobial. She also shares what the drug’s unique mechanism of action is.
Newsletter
Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Contagion Live
1
Measles Update: February 6, 2026
2
Pritelivir Improves Outcomes in Immunocompromised Patients With Refractory Herpes Simplex Virus
3
HIV in the Black Community: Shifting from Stigma and Health Inequalities to Communication and Care Initiatives
4
Antibiotics Deconstructed: IV Fosfomycin
5

































































































































